Seleccione otro país
Bienvenido a Lyxor EspañaWelcome
Por favor, lea la información importante aquí incluida antes de continuar a nuestra página web

Información relevante 

Los Lyxor ETFs presentados en la página web de lyxoretf.com, pueden ser objeto de restricciones en lo que respecta a la inversión por determinadas personas o en determinados países, en virtud de las distintas regulaciones nacionales aplicables a dichas personas o en dichos países. Cualquier persona que acceda a esta página web desde una jurisdicción en la cual se aplican dichas restricciones tiene que informarse al respecto y observar dichas restricciones. Por consiguiente, le corresponde a usted asegurarse de que, efectivamente está autorizado a invertir en los Lyxor ETFs presentados en esta página web. Invirtiendo en estos productos, usted garantiza a Société Générale que está efectivamente autorizado a invertir. Inversores españoles se deben dirigir a www.lyxoretf.es

La información contenida en esta página web no constituye una oferta o invitación para adquirir o vender los productos aquí descritos a personas sometidas a  jurisdicciones donde:

(a) dicha oferta o invitación no esté autorizada;
(b) Lyxor Asset Management no esté cualificada para hacer dicha oferta o invitación;
(c)  sea ilícito hacer dicha oferta o invitación.

Los ETFs referidos en esta página web no han estado y no estarán registrados conforme al U.S Securities Act de1933, por lo tanto, no pueden ser ofertados ni vendidos en los EE.UU sin registro previo o solo en caso de excepción de registro conforme al  al Securities Act. Por consiguiente, los ETFs listados en esta página web no pueden ser vendidos a “U.S persons”, ni transferidos a los Estados Unidos a menos que dicha transacción esté sujeta a los requisitos de registro conforme a la ley Americana.

Esta página web es de carácter comercial y no de carácter legal. No se garantiza la exactitud, exhaustividad o pertinencia de la información aunque ha sido establecida a partir de fuentes consideradas como fiables.
La información presentada en esta página web se basa en información de mercado constada en un momento dado que puede variar con posterioridad a su publicación. El valor de reembolso de los Lyxor ETFs puede ser inferior al montante de la inversión inicial. En el peor de los casos, los inversores podrían perder hasta la totalidad de su inversión, por lo que se recomienda a los inversores consultar la sección« factores de riesgo » del folleto del producto. El precio de algunos Lyxor ETFs puede ser sensible a riesgos de tipo de cambio entre la cotización del ETF y/o la divisa del índice y/o la divisa del componente del índice.

Todos los LyxorETFs presentados en esta página web han sido aprobados por la “Autorité des Marchés Financiers (AMF)” y son objeto de un folleto aprobado por la AMF y pasaporteado en la CNMV conforme a la Directiva 2003/71/CE. Dichos folletos están disponibles en esta página Web.

La documentación relativa a los Lyxor ETFs preverá métodos de ajuste y de sustitución para tener en cuenta que consecuencias tendría cualquier suceso extraordinario que afecte a uno o varios de los subyacentes de estos productos.

Antes de invertir en un Lyxor ETF, usted debe hacer su propia valoración del riesgo desde un punto de vista legal, fiscal y  contable, sin depender exclusivamente de la información que le proporcionamos y consultando, si lo estima necesario, sus propios asesores en la materia o cualquier otro asesor independiente.

El inversor de ETFs estará expuesto a los siguientes factores de riesgo: Riesgo de pérdida del capital invertido, al no existir ninguna garantía, como consecuencia de un movimiento desfavorable del Índice de Referencia, Riesgo de que el objetivo de gestión solo se cumpla parcialmente, Riesgo de contrapartida como resultado de la utilización de los instrumentos financieros (OTC) formalizados con un establecimiento de crédito. Se recomienda a los inversores que consulten la sección del folleto antes de invertir.

En la medida en que cumpla con la legislación aplicable, ninguna entidad del Grupo Société Générale acepta responsabilidad alguna por las consecuencias financieras o de cualquier otra naturaleza que resulten de la inversión en este producto.

27 sep 2021

Podcast: Giving genes the silent treatment, with Dicerna Pharmaceuticals

In our latest episode of One Step Ahead – our podcast designed to help future-proof your portfolio – we put the spotlight on Dicerna Pharmaceuticals, an innovator in gene-based medicine and a holding of our Disruptive Technology ETF.

Dicerna Pharmaceuticals is a Massachusetts based biopharmaceutical company specialised in “RNA interference” (RNAi), a ground-breaking technique that can target and silence certain disease-causing genes in order to restore patients’ health, and improve their quality of life.

To help us understand RNAi, and what the future of gene-based medicine holds for us, we spoke to Douglas Fambrough, Ph.D., Dicerna’s CEO and President. From kidney-related disease to neurological disorders – and potentially even alcohol use disorder – he asserts that gene-based medicines have the potential to be a safe and effective approach to treating disease. According to Dr. Fambrough, we’re at the early stages of a “big bang” for gene-based medicine, and RNAi is just one of many disruptive technologies set to change the future of healthcare.​

douglas

Douglas Fambrough     
President and CEO, 

Dicerna Pharmaceuticals

Below are a few edited highlights from the episode. You can listen to the full episode on your favourite podcast platform (including Spotify, Apple Podcasts, Google Podcasts, Stitcher) or right here on the Lyxor ETF website:

Libby: Doug, the phrase “we interfere” is repeated in many places on Dicerna’s website. Can you explain to our listeners what it is you mean by that?

Douglas: I'd be happy to explain. We intended that phrase to be a little startling and a little unusual to capture attention. At Dicerna, we interfere with disease. Disease processes divert people from their normal life in terrible ways, and we want to interfere with the ability of the disease to do that.

The phrase plays off the name of the technology we use, which is called RNA interference. And so for those technically in the know, it's a play on the word ‘interfere’, but it's designed to sort of grab your attention and show that we're interfering with disease. That's what we do to try and restore health.

Libby: There's been a lot of buzz around advances in healthcare innovation and genomics, with terminology like mRNA, gene therapy, and gene editing all making headlines, particularly with Covid-19 vaccines. Would you mind briefly explaining the differences between these concepts, and how Dicerna’s gene silencing approach is different?

Douglas: I think we all know the machinery of our body that operates every day – it’s primarily made of proteins. (…) But then we have a genetic code, or the ‘instruction set’ that encodes all the directions to make all of these proteins. And you can think of our genome – this genetic instruction set – as an enormous recipe book with 20 to 30 thousand pages and a recipe on each page to make a protein.

Now, if you think of that as a recipe book, and each protein is maybe a dish that's made, you could never bring a book that big to the kitchen counter. So you have to make a copy of a page and bring it over to the counter in order to make the protein. Traditionally drugs were made to interfere with the actual machinery, to interact with the proteins that are made.

But all of the technologies you mentioned are about instead looking at the genetic instruction set, and they either work on that big recipe book or on the copy that's made of the particular page. (…)

  • mRNA is the copy that's made of one page of the recipe book of the genome to encode for a specific protein. What mRNA companies do is they provide a copy from the outside. In the case of the vaccines, they provide a copy of a viral protein that your body then makes into the viral protein so your immune system can recognise it. Now, it's not the full virus, so it's not infectious. But this is good for when a patient is missing a gene. You can put the copy for that gene back in so the protein could be made. Or if you need more of the activity of one gene, if you’re low on a hormone or something, you can put in a copy and make more of the hormone.

  • What we do is the flip side of that. If you have too much of one of the genes, RNA interference disrupts the ability to read out the copy of the gene. In fact, sometimes it's called gene silencing. It prevents the gene from being made into the protein. A lot of common diseases, whether cardiovascular, acid stomach, autoimmune, or inflammatory diseases – they involve where there's too much of a biological process going on. (…) 

The other technologies you mentioned [gene therapy, gene editing] operate on the instruction set itself. Now, the instruction set is permanent; the copies are transitory. So when you intervene with the copies, with mRNA or RNA interference, it lasts for a little while, then it fades away and you have to give the drug again. But technologies that work on the instruction set – they’re lifelong and permanent, so one would want to be very careful.

  • Gene therapy, as it's normally called, is basically putting a new page into the genome. And so if one of the pages is missing or just damaged so that it doesn't function properly, you can put a brand new page and an extra page that replaces the defective page. This is particularly good for genetic diseases where a gene is missing or someone inherits a defective copy of a gene from both parents. (…)

  • The last technology, which is the newest and youngest and has no approved products today unlike the other three, is gene editing. That is going in and kind of literally editing the words on the individual pages. One simple way to edit is just to kind of erase stuff and take a page and break it. That's a bit like RNA interference in that you turn the gene off by breaking it at the instruction set level. And that would be lifelong. (…) And the other way to do it, which is a little harder and a little earlier in the technology development process, is actually fix a mistake. So take a page that was incorrectly written and make it the proper code again. (…)

Libby: What is the potential for Dicerna to treat diseases outside of the liver? ​

Douglas: The liver for a variety of reasons is the easiest tissue to do RNA interference in. But having figured out how to make it work in liver and optimise it in liver, that really taught us how we could modify the technology in fairly subtle ways in order to get to other tissues in the body, such as lung tissue, fat tissue, and tissues or cells that are part of the immune system. And that opens up a huge variety of indications.

Also, the central nervous system for diseases like chronic pain or neurodegenerative diseases like Alzheimer's or Parkinson's are far more applications of the technology than Dicerna could do on our own.

And that's why we have collaborations with companies like Roche and Eli Lilly and Novo Nordisk to move into these other therapeutic areas, some of which are very, very large and we couldn't do on our own. For example, the hepatitis B virus with hundreds of millions of patients globally – we're working with Roche on that programme, a large global multinational with global reach. 

Catch up on the rest of the conversation in the full episode of One Step Ahead.

This episode contains forward-looking statements and actual results may be materially different; see “Risk Factors” under Dicerna’s latest SEC filings. 


Relevant ETFs

At the time of this podcast recording, Dicerna Pharmaceuticals was a holding in our SFDR 8 compliant Lyxor MSCI Disruptive Technology ESG Filtered (DR) UCITS ETF (Bloomberg ticker: UNIC).

Swiss healthcare giant Roche, with which Dicerna has partnered on an RNAi therapeutic for the treatment of the hepatitis B virus, is also a holding of our Disruptive Technology ETF.

Learn more about our Thematic ETFs​

This podcast is for informational purposes only, and should not be taken as investment advice and/or an offer to buy financial products. Lyxor International Asset Management, holding the brand Lyxor ETF, does not in any way endorse or promote any companies or securities mentioned in this show. The opinions expressed at the time of recording do not necessarily reflect the views of Lyxor ETF or its parent company, Societe Generale, and may vary from time to time.

Risk Warning

This document is for the exclusive use of investors acting on their own account and categorised either as “Eligible Counterparties” or “Professional Clients” within the meaning of Markets in Financial Instruments Directive 2014/65/EU. These products comply with the UCITS Directive (2009/65/EC). Société Générale and Lyxor International Asset Management (LIAM) recommend that investors read carefully the “investment risks” section of the product’s documentation (prospectus and KIID). The prospectus and KIID are available free of charge on www.lyxoretf.com, and upon request to client-services-etf@lyxor.com.

Except for the United-Kingdom, where this communication is issued in the UK by Lyxor Asset Management UK LLP, which is authorized and regulated by the Financial Conduct Authority in the UK under Registration Number 435658, this communication is issued by Lyxor International Asset Management (LIAM), a French management company authorized by the Autorité des marchés financiers and placed under the regulations of the UCITS (2014/91/EU) and AIFM (2011/61/EU) Directives. Société Générale is a French credit institution (bank) authorised by the Autorité de contrôle prudentiel et de résolution (the French Prudential Control Authority).

The products mentioned are the object of market-making contracts, the purpose of which is to ensure the liquidity of the products on the London Stock Exchange, assuming normal market conditions and normally functioning computer systems. Units of a specific UCITS ETF managed by an asset manager and purchased on the secondary market cannot usually be sold directly back to the asset manager itself. Investors must buy and sell units on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees for doing so. In addition, investors may pay more than the current net asset value when buying units and may receive less than the current net asset value when selling them. Updated composition of the product’s investment portfolio is available on www.lyxoretf.com. In addition, the indicative net asset value is published on the Reuters and Bloomberg pages of the product, and might also be mentioned on the websites of the stock exchanges where the product is listed.

Prior to investing in the product, investors should seek independent financial, tax, accounting, and legal advice. It is each investor’s responsibility to ascertain that it is authorised to subscribe, or invest into this product. This document is of a commercial nature and not of a regulatory nature. This material is of a commercial nature and not a regulatory nature. This document does not constitute an offer, or an invitation to make an offer, from Société Générale, Lyxor Asset Management (together with its affiliates, Lyxor AM) or any of their respective subsidiaries to purchase or sell the product referred to herein.

Research disclaimer

Lyxor International Asset Management (“LIAM”) or its employees may have or maintain business relationships with companies covered in its research reports. As a result, investors should be aware that LIAM and its employees may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see appendix at the end of this report for the analyst(s) certification(s), important disclosures, and disclaimers. Alternatively, visit our global research disclosure website www.lyxoretf.com/compliance.

Conflicts of interest

This research contains the views, opinions, and recommendations of Lyxor International Asset Management (“LIAM”) Cross Asset and ETF research analysts and/or strategists. To the extent that this research contains trade ideas based on macro views of economic market conditions or relative value, it may differ from the fundamental Cross Asset and ETF Research opinions and recommendations contained in Cross Asset and ETF Research sector or company research reports and from the views and opinions of other departments of LIAM and its affiliates. Lyxor Cross Asset and ETF research analysts and/or strategists routinely consult with LIAM sales and portfolio management personnel regarding market information including, but not limited to, pricing, spread levels and trading activity of ETFs tracking equity, fixed income, and commodity indices. Trading desks may trade, or have traded, as principal on the basis of the research analyst(s) views and reports. Lyxor has mandatory research policies and procedures that are reasonably designed to (i) ensure that purported facts in research reports are based on reliable information and (ii) to prevent improper selective or tiered dissemination of research reports. In addition, research analysts receive compensation based, in part, on the quality and accuracy of their analysis, client feedback, competitive factors and LIAM’s total revenues including revenues from management fees and investment advisory fees and distribution fees.

Connect with us on linkedin